In vivo SPECT imaging of tumors by 198,199Au-labeled graphene oxide nanostructures

Fazaeli, Yousef; Akhavan, Omid; Rahighi, Reza; Aboudzadeh, Mohammad Reza; Karimi, Elham; Afarideh, H.

doi:10.1016/j.msec.2014.09.019

Cited by 120 publications

(54 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the excretion profile of CNHs functionalized by [ 111 In]DTPA was different from Gd 2 O 3 -labeled CNHs (100 nm aggregates) coated with DSPE-PEG 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(PEG)] (5 kDa), 37 that were mainly excreted via the liver-bile ductduodenum route. 37 The similar results from single-wall carbon nanotubes (SWNTs) and graphene oxide also indicated that DTPA-functionalized SWNTs [27][28][29] or graphene oxide 43 exhibited faster clearance from the body than PEG-modified CNTs or graphene. 44 Therefore, we think that the surface functionalization of CNHs with non-bulky functional groups, like DTPA, can lead to a different biodistribution and excretion kinetic profile.…”

mentioning

confidence: 88%

Radiolabeling, whole-body single photon emission computed tomography/computed tomography imaging, and pharmacokinetics of carbon nanohorns in mice

Zhang

Jasim

Ménard‐Moyon

et al. 2016

IJN

View full text Add to dashboard Cite

In this work, we report that the biodistribution and excretion of carbon nanohorns (CNHs) in mice are dependent on their size and functionalization. Small-sized CNHs (30–50 nm; S-CNHs) and large-sized CNHs (80–100 nm; L-CNHs) were chemically functionalized and radiolabeled with [ 111 In]-diethylenetriaminepentaacetic acid and intravenously injected into mice. Their tissue distribution profiles at different time points were determined by single photon emission computed tomography/computed tomography. The results showed that the S-CNHs circulated longer in blood, while the L-CNHs accumulated faster in major organs like the liver and spleen. Small amounts of S-CNHs- and L-CNHs were excreted in urine within the first few hours postinjection, followed by excretion of smaller quantities within the next 48 hours in both urine and feces. The kinetics of excretion for S-CNHs were more rapid than for L-CNHs. Both S-CNH and L-CNH material accumulated mainly in the liver and spleen; however, S-CNH accumulation in the spleen was more prominent than in the liver.

show abstract

mentioning

confidence: 88%

Radiolabeling, whole-body single photon emission computed tomography/computed tomography imaging, and pharmacokinetics of carbon nanohorns in mice

Zhang

Jasim

Ménard‐Moyon

et al. 2016

IJN

View full text Add to dashboard Cite

show abstract

“…Fazaeli et al developed a SPECT imaging agent by labeling GO nanosheets with 198;199 Au and demonstrated targeted SPECT imaging of tumors. 138 In vivo SPECT imaging of Her2 positive tumors was demonstrated by Cornelissen et al using 111 In-benzyl-diethylenetriaminepentaacetic acid (BnDTPA) labelled anti-Her2 antibody conjugated nGO as the imaging agents. 139 The authors observed that the radiolabeled nanoconstructs showed better pharmacokinetic pro¯les as compared to radiolabeled antibody alone.…”

Section: Radioactive Imagingmentioning

confidence: 99%

Graphene-Based Nanomaterials for Theranostic Applications

Roy

Jaiswal

2017

Rep. Adv. Phys. Sci.

View full text Add to dashboard Cite

Graphene and graphene-based nanomaterials such as graphene oxide (GO), reduced graphene oxide (rGO) and graphene quantum dots (GQDs) have gained a lot of attention from diverse scienti¯c¯elds for applications in sensing, catalysis, nanoelectronics, material engineering, energy storage and biomedicine due to its unique structural, optical, electrical and mechanical properties. Graphene-based nanomaterials emerge as a novel class of nanomedicine for cancer therapy for several reasons. Firstly, its structural properties like high surface area and aromaticity enables easy loading of hydrophobic drugs. Secondly, presence of oxygen containing functional groups improve its physiological stability and also act as site for biofunctionalization. Thirdly, its optical absorption in the NIR region enable them to act as photoagents for photothermal and photodynamic therapies of cancer, both in vitro and in vivo. Finally, its intrinsic°u orescence property helps in bioimaging of cancer cells. Overall, graphene-based nanomaterials can act as agents for developing multifunctional theranostic platforms for carrying out more e±cient detection and treatment of cancers. This review provides a detailed summary of the di®erent applications of graphene-based nanomaterials in drug delivery, nucleic acid delivery, phototherapy, bioimaging and theranostics.

show abstract

“…The thin sheets used in this study presented that dimensions and surface groups are essential to determine its ability to cross the renal filtration slit (<40 nm). Another report supported the phenomenon of urinary excretion via kidney for Au-labeled graphene oxide [40]. 198,199 Au-labeled GO was used to target and to image tumors.…”

mentioning

confidence: 93%

“…The characteristics of Au to interact with the negatively charged cells and sub-cellular membranes allows efficient cancer cell targeting whilst the high loading capacity ensures greater amounts of Au to be grafted onto the nano-conveyor. The low lipophilicity of the particle allows rapid clearing of the particles by the kidneys within 24 h [40].…”

mentioning

confidence: 99%

Radio-graphene in Theranostic Perspectives

Hwang

2016

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Owing to its unique physicochemical properties such as high surface area, notable biocompatibility, robust mechanical strength, high thermal conductivity, and ease of functionalization, 2D-layered graphene has received tremendous attention as a futuristic nanomaterial and its-associated research has been rapidly evolving in a variety of fields. With the remarkable advances of graphene especially in the biomedical realm, in vivo evaluation techniques to examine in vivo behavior of graphene are largely demanded under the hope of clinical translation. Many different types of drugs such as the antisense oligomer and chemotherapeutics require optimal delivery conveyor and graphene is now recognized as a suitable candidate due to its simple and high drug loading property. Termed as 'radio-graphene', radioisotope-labeled graphene approach was recently harnessed in the realm of biomedicine including cancer diagnosis and therapy, contributing to the acquisition of in vivo information for targeted drug delivery. In this review, we highlight current examples for bioapplication of radiolabeled graphene with brief perspectives on future strategies in its extensive bio-or clinical applications.

show abstract

In vivo SPECT imaging of tumors by 198,199Au-labeled graphene oxide nanostructures

Cited by 120 publications

References 68 publications

Radiolabeling, whole-body single photon emission computed tomography/computed tomography imaging, and pharmacokinetics of carbon nanohorns in mice

Radiolabeling, whole-body single photon emission computed tomography/computed tomography imaging, and pharmacokinetics of carbon nanohorns in mice

Graphene-Based Nanomaterials for Theranostic Applications

Radio-graphene in Theranostic Perspectives

Contact Info

Product

Resources

About